Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration.

-- These results support the further clinical development of INNA-051 to mitigate the impact of natural infection by respiratory viruses such as SARS-CoV-2 and its variants: influenza, RSV, and the common cold, in individuals at risk of more severe illness.

MELBOURNE, Australia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of respiratory viral infections, was found to significantly impact the course of viral infection in a Phase 2a flu challenge study.

The study included 123 adults (ages 19 to 53) randomized to receive two doses of INNA-051 (low and high dose) or placebo, then challenged with a substantial dose of H3N2 influenza A virus. The viral inoculum was expected to result in a large majority of participants being infected. Interpretation of the study was complicated by lower than anticipated rates of infection in the placebo arm and an unexpectedly large proportion of participants having pre-existing immunity to the challenge strain across all groups (assessed using the hemagglutination inhibition assay). Post hoc analyses excluding those with pre-existing immunity showed that INNA-051-treated participants with PCR laboratory-confirmed infection had a statistically significant shorter duration of infection. This effect was greater with the higher dose. Although not statistically significant, a dose-related reduction in the duration of symptoms was also observed.

Notably, the study confirmed the safety profile of INNA-051. Compared with the placebo group, participants receiving INNA-051 showed no increase in the incidence, magnitude, or duration of any flu symptom, nor enhanced local or systemic signs or symptoms associated with the viral challenge. The most common adverse events associated with the study medication were mild, short-lived and similar to those observed during the initial Phase 1 study.

“This study further supports the concept that boosting the local innate immune response to common respiratory viruses has potential clinical benefit. In this study, INNA-051 was found to be safe and to significantly impact the course of infection. We are eager to investigate INNA-051’s clinical benefit in the context of natural viral respiratory tract infections in individuals at increased risk of more severe illness,” said Christophe Demaison PhD, Managing Director and CEO of ENA Respiratory.

Earlier research in humans and animals has shown that INNA-051 activates the innate immune system in the nose, a common site of infection. These Phase 2a study results mirror those seen in animal respiratory infection models, and are consistent with the INNA-051 mechanism of action. INNA-051 accelerates virus clearance and reduces virus spread to other parts of the body. It is anticipated that INNA-051 prophylaxis will reduce illness severity and healthcare utilization in individuals exposed to respiratory viral infections, especially in those at high risk of complications.

“Many people around the world have now been impacted by a ‘tripledemic’ of flu, RSV and SARS-Cov-2 viruses that have been circulating together in recent months. The surge in illness and hospitalization demonstrates the urgent need for a broad-spectrum treatment to boost immunity against common respiratory illnesses, and these data suggest INNA-051 is a promising option,” said Scott White MD, Chief Medical Officer, ENA Respiratory.

Notes to Editors

If you would like to arrange an interview, please contact:

  • Glenn Silver, Finn Partners, +1 973 818 8198, glenn.silver@finnpartners.com

About ENA Respiratory and INNA-051

ENA Respiratory aims to transform the prevention of respiratory viral infections in populations at-risk of complications. The company is based in Melbourne and Sydney, Australia, and it has secured a Series A investment from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

INNA-051 is a potent innate immune TLR2/6 agonist. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. It is being developed for intranasal delivery to target the primary entry site of viral respiratory infections, as most respiratory viruses, including SARS-CoV-2 and influenza, initially infect and replicate in nasal mucosa epithelial cells. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

Key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

For more information, please visit https://enarespiratory.com.



Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

THỦ THUẬT HAY

Hosts Go - Ứng dụng hỗ trợ chỉnh sửa file Host trên thiết bị Android mà không cần root

Về cơ bản, Hosts Go cho phép người dùng thay đổi địa chỉ máy chủ DNS và Hosts để truy cập tới các trang web bị chặn/giới hạn tốc độ hoặc chặn nhiều loại quảng cáo phiền phức mà không cần tới quyền root, đặc biệt là

Cách chọn mua ổ cứng laptop Dell, HP, Lenovo, Asus

Ô cứng laptop của bạn bị bad hay đơn giản bạn chỉ muốn nâng cấp ổ cứng để xử lý dữ liệu cũng như lưu trữ dữ liệu được nhiều hơn. Tham khảo bài viết dưới đây để có cho mình cách chọn mua ổ cứng laptop hiệu quả mà hợp lý

Một số tổ hợp phím tắt hữu ích có trên macOS

Về cơ bản, phím Command (⌘) sẽ có chức năng tương tự với Ctrl (Control) trên các máy tính thông thường. Tuy nhiên, trên macOS sẽ có đôi chút khác biệt về cách dùng, từ cả những điều đơn giản như di chuyển (move).

Tin vui dành cho tín đồ "tự sướng" bằng điện thoại, ứng dụng Microsoft Selfie đã có trên Android

Sau 11 tháng có mặt trên hệ điều hành iOS, Microsoft Selfie đã chính thức có mặt trên Google Play. Ngay bây giờ bạn có thể tải về và trả nghiệm những tính năng hay ho của Microsoft Selfie để cho ra những bức anh 'tự

ĐÁNH GIÁ NHANH

Trên tay và đánh giá nhanh Coolpad Max: Phablet hoàn thiện tốt, cấu hình khá, phần mềm hấp dẫn

Mở hộp và trên tay nhanh Coolpad Max, chiếc phablet trung cao chuẩn bị lên kệ tại thị trường Việt Nam

Đánh giá Kawasaki Bajaj Pulsar 200NS: Môtô giá rẻ cho giới trẻ

Mẫu môtô giá rẻ Kawasaki Bajaj Pulsar 200NS 2016 được nhập khẩu nguyên chiếc về Việt Nam nổi bật với thiết kế mạnh mẽ, tay lái rộng cùng giá bán khá mềm chỉ 78 triệu đồng.

Đánh giá Xiaomi Redmi Note 5A Prime - có “ngon - bổ - rẻ” với mức giá 4 triệu đồng?

Với cấu hình khá tốt nhờ con chip Snapdragon 435, 3GB RAM và đặc biệt là bộ đôi camera tới 13MP/16MP giúp cho Redmi Note 5A Prime trở thành một trong những chiếc smartphone nổi bật trong phân khúc 4 triệu đồng. Dưới đây